Loading
Locally Advanced Unresectable NSCLC / Locally Advanced Metastatic NSCLC / AMG 510 · Interventional Study
ClinicalTrials.gov · August 20, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registry record for an expanded access programme of sotorasib (AMG 510) in patients with KRAS p.G12C-mutant NSCLC that is no longer recruiting. No safety, efficacy or outcome data are reported in this registry entry; the record documents the programme structure and intended population only.
Expanded Access. Non Small-cell Lung Cancer, Locally Advanced Unresectable NSCLC, Locally Advanced Metastatic NSCLC; age from 18 Years; to 99 Years. Intervention: AMG 510. 55 sites across 6 countries.
This is a registry record for an expanded access programme of sotorasib (AMG 510) in patients with KRAS p.G12C-mutant NSCLC that is no longer recruiting. No safety, efficacy or outcome data are reported in this registry entry; the record documents the programme structure and intended population only.
Registry record describes study design and objectives only; no results, safety data, or outcome measures are reported. No efficacy endpoints, adverse event counts, or comparative data are available.
Expanded access programmes provide investigational treatment outside of formal trials to patients who meet eligibility criteria but lack standard treatment options. This record alone does not convey safety or efficacy findings and should not be used to guide clinical practice without reference to controlled trial data.
This is a clinical trial registry record describing an expanded access programme with no results reported; it documents a planned intervention in a defined population but carries no efficacy or safety outcome data.
As stated by the source record.
Quoted from the source exactly as published.
Expanded access programmes provide investigational treatment outside of formal trials to patients who meet eligibility criteria but lack standard treatment options. This record alone does not convey safety or efficacy findings and should not be used to guide clinical practice without reference to controlled trial data.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04667234). This is a study registration, not published results. Lead sponsor: Amgen. Recruitment status: NO_LONGER_AVAILABLE. Study type: EXPANDED_ACCESS. Conditions: Non Small-cell Lung Cancer, Locally Advanced Unresectable NSCLC, Locally Advanced Metastatic NSCLC. Interventions: DRUG: AMG 510. Brief summary: The primary objective of this study is to provide expanded access to and characterize the safety profile of Sotorasib in participants with previously treated locally advanced/unresectable/metastatic non small-cell lung cancer (NSCLC) with KRAS p.G12C mutation in a real-world setting.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.